Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis
Johannes F.E. Mann, John B. Buse, Thomas Idorn, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 9, pp. 2058-2066
Open Access | Times Cited: 60

Showing 1-25 of 60 citing articles:

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
Vlado Perkovic, Katherine R. Tuttle, Peter Rossing, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 2, pp. 109-121
Closed Access | Times Cited: 471
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Lawrence Blonde, Guillermo E. Umpierrez, Sarah Reddy, et al.
Endocrine Practice (2022) Vol. 28, Iss. 10, pp. 923-1049
Open Access | Times Cited: 321
Molecular mechanisms and therapeutic targets for diabetic kidney disease
Katherine R. Tuttle, Rajiv Agarwal, Charles E. Alpers, et al.
Kidney International (2022) Vol. 102, Iss. 2, pp. 248-260
Open Access | Times Cited: 309
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
Ahmed M. Shaman, Stephen C. Bain, George L. Bakris, et al.
Circulation (2021) Vol. 145, Iss. 8, pp. 575-585
Open Access | Times Cited: 170
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
Peter Rossing, Florian M.M. Baeres, George L. Bakris, et al.
Nephrology Dialysis Transplantation (2023) Vol. 38, Iss. 9, pp. 2041-2051
Open Access | Times Cited: 154
Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression
Sandra Naaman, George L. Bakris
Diabetes Care (2023) Vol. 46, Iss. 9, pp. 1574-1586
Open Access | Times Cited: 112
The cardio-renal-metabolic connection: a review of the evidence
Marella Marassi, Gian Paolo Fadini
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 88
Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo
Katherine R. Tuttle, Heidrun Bosch‐Traberg, David Z.I. Cherney, et al.
Kidney International (2023) Vol. 103, Iss. 4, pp. 772-781
Open Access | Times Cited: 76
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Helen M. Colhoun, Ildiko Lingvay, Paul Brown, et al.
Nature Medicine (2024) Vol. 30, Iss. 7, pp. 2058-2066
Open Access | Times Cited: 66
Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91)
Amanda Adler, Ruth L. Coleman, José Leal, et al.
The Lancet (2024) Vol. 404, Iss. 10448, pp. 145-155
Closed Access | Times Cited: 44
Combination therapy for kidney disease in people with diabetes mellitus
Daniël H. van Raalte, Petter Bjornstad, David Z.I. Cherney, et al.
Nature Reviews Nephrology (2024) Vol. 20, Iss. 7, pp. 433-446
Closed Access | Times Cited: 32
KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD
Sankar D. Navaneethan, Nisha Bansal, Kerri L. Cavanaugh, et al.
American Journal of Kidney Diseases (2024)
Closed Access | Times Cited: 17
GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study
Babak J. Orandi, Yusi Chen, Yiting Li, et al.
The Lancet Diabetes & Endocrinology (2025) Vol. 13, Iss. 5, pp. 374-383
Closed Access | Times Cited: 2
The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes
Merlin C. Thomas, Melinda T. Coughlan, Mark E. Cooper
Cell Metabolism (2023) Vol. 35, Iss. 2, pp. 253-273
Open Access | Times Cited: 33
Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future
Irene Caruso, Francesco Giorgino
Endocrine (2024) Vol. 84, Iss. 3, pp. 822-835
Open Access | Times Cited: 14
Anti-inflammatory benefits of semaglutide: State of the art
Habib Yaribeygi, Mina Maleki, Tannaz Jamialahmadi, et al.
Journal of Clinical & Translational Endocrinology (2024) Vol. 36, pp. 100340-100340
Open Access | Times Cited: 13
Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials
Jui‐Yi Chen, Tsuen‐Wei Hsu, Jung-Hua Liu, et al.
American Journal of Kidney Diseases (2025)
Open Access | Times Cited: 1
Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis
Hiddo J.L. Heerspink, Naveed Sattar, Imre Pávó, et al.
Diabetes Care (2023) Vol. 46, Iss. 8, pp. 1501-1506
Open Access | Times Cited: 21
Potential Mediators for Treatment Effects of Novel Diabetes Medications on Cardiovascular and Renal Outcomes: A Meta‐Regression Analysis
José M. Rodriguez‐Valadez, Malak Tahsin, Umesh Masharani, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 4
Open Access | Times Cited: 6
Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6
Ellen M. Apperloo, David Z.I. Cherney, Anja Birk Kuhlman, et al.
Nephrology Dialysis Transplantation (2024)
Open Access | Times Cited: 6
Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular and renal outcomes: A meta‐analysis and meta‐regression analysis
Satoshi Yoshiji, Hiroto Minamino, Daisuke Tanaka, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 6, pp. 1029-1037
Closed Access | Times Cited: 24
The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice
Bernt Johan von Scholten, Frederik Flindt Kreiner, Søren Rasmussen, et al.
Therapeutic Advances in Endocrinology and Metabolism (2022) Vol. 13
Open Access | Times Cited: 23
Albuminuria‐lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo‐controlled study
Suvanjaa Sivalingam, Victor Wasehuus, Viktor Rotbain Curovic, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 1, pp. 54-64
Open Access | Times Cited: 15
Mechanisms and clinical applications of incretin therapies for diabetes and chronic kidney disease
Radica Z. Alicic, Joshua J. Neumiller, Katherine R. Tuttle
Current Opinion in Nephrology & Hypertension (2023)
Open Access | Times Cited: 13
Potential kidney protective effects of glucagon‐like peptide‐1 receptor agonists
Philippa Trevella, Elif I. Ekinci, Richard J. MacIsaac
Nephrology (2024) Vol. 29, Iss. 8, pp. 457-469
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top